Clinical Trial

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally advanced nasopharyngeal carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-23; most recent amendment 2026-02-14.
Status change: Not Yet Recruiting → Recruiting 2024-08-04
Trial Details
NCT Number NCT06059261
Lead Sponsor Chongqing University Cancer Hospital
Conditions Nasopharyngeal Carcinoma
Enrollment 30 participants
Start Date 2026-02-09
Primary Completion 2027-02-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-18